All protocols
Other / Specialty

Carnosine Peptide Protocol & Dosing

Updated 1w ago 4 min read 15+ helpful
Validity Score

Validity Score

9 Speculative
Evidence 42
Community 35
Completeness 43
Actionability 40
Coverage 80
Penalty -34

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

Carnosine (β-alanyl-L-histidine) is a naturally occurring dipeptide concentrated in muscle and brain tissue, studied for antioxidant, anti-glycation, and carbonyl-scavenging activity. Unlike most entries in this index it is not an injectable research peptide — it is an oral supplement-grade dipeptide widely used in aging and exercise research.

Evidence boundary

Oral supplement use with a substantial human literature, mostly dietary-supplement context. Research use is limited to laboratory and education contexts.

Trial evidence

  • Human studies cover carnosine’s antioxidant status, exercise performance, and anti-glycation/advanced-glycation-end-product (AGE) contexts.

Preparation and measurement

Oral dosing — no reconstitution. Typically taken as powder or capsule.

Concentration matches.

Reference schedule

Reference schedule
PhaseDoseDraw / measureFrequencyWeekly total
Standard research1 gOral1× daily7 g/week
Higher end2 gOral1–2× daily14 g/week

Standard research

Dose
1 g
Draw / measure
Oral
Frequency
1× daily
Weekly total
7 g/week

Higher end

Dose
2 g
Draw / measure
Oral
Frequency
1–2× daily
Weekly total
14 g/week

Weekly totals apply only during the active phase.

Titration rules

  • Common range: 1–2 g per day, once or twice daily, for 12–14 week study periods.
  • Not an injection; no BAC, no syringe math — an oral dipeptide.
  • Could be co-studied with beta-alanine loading (carnosine’s rate-limiting precursor).
Was this protocol helpful?
Share via